Leslie Trigg Sells 2,120 Shares of Outset Medical (NASDAQ:OM) Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 2,120 shares of the firm’s stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $5.05, for a total transaction of $10,706.00. Following the sale, the chief executive officer owned 105,703 shares in the company, valued at approximately $533,800.15. This trade represents a 1.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Leslie Trigg also recently made the following trade(s):

• On Tuesday, January 20th, Leslie Trigg sold 11,794 shares of Outset Medical stock. The stock was sold at an average price of $5.12, for a total transaction of $60,385.28.
• On Wednesday, January 7th, Leslie Trigg sold 1,795 shares of Outset Medical stock. The shares were sold at an average price of $4.27, for a total value of $7,664.65.
• On Monday, November 17th, Leslie Trigg sold 916 shares of Outset Medical stock. The shares were sold at an average price of $4.60, for a total value of $4,213.60.

Outset Medical Trading Up 3.8%

Shares of OM stock opened at $5.40 on Friday. The business has a 50-day moving average price of $4.34 and a two-hundred day moving average price of $10.99. Outset Medical, Inc. has a 12-month low of $3.10 and a 12-month high of $21.98. The company has a quick ratio of 5.77, a current ratio of 7.09 and a debt-to-equity ratio of 0.69. The firm has a market cap of $98.01 million, a P/E ratio of -0.41 and a beta of 2.07.

Key Stories Impacting Outset Medical

Here are the key news stories impacting Outset Medical this week:

• Positive Sentiment: Intraday strength: OM is trading up today on relatively light volume, which may reflect a short-term technical bounce or buying into recent weakness. MarketBeat Trading Note
• Neutral Sentiment: Mixed analyst and technical backdrop — consensus ratings remain around “Moderate Buy” but recent downgrades and lower price targets have appeared; OM’s 50-day moving average (~$4.33) is well below its 200-day (~$11.03) and the stock sits nearer its 52‑week low than its high. These factors create mixed medium‑term pressure despite today’s move. MarketBeat Stock Page
• Negative Sentiment: CEO selling: CEO Leslie Trigg disclosed sales totaling 13,914 shares across Jan. 20–21 (including 11,794 and 2,120-share trades) at roughly $5.12–$5.05, trimming her stake. Insider CEO sales are typically viewed negatively by investors. CEO SEC Filing
• Negative Sentiment: Other senior exec selling: General Counsel John Brottem and EVP Marc Nash disclosed multi‑thousand‑share sales across Jan. 20–21 (Brottem ~10,494 shares, one filing showing ~20% reduction; Nash ~6,355 shares across filings), further increasing selling pressure from insiders. GC SEC Filing EVP SEC Filing

Institutional Investors Weigh In On Outset Medical

A number of large investors have recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. purchased a new position in shares of Outset Medical during the third quarter valued at approximately $5,324,000. Geode Capital Management LLC lifted its stake in Outset Medical by 955.9% in the second quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock worth $7,984,000 after acquiring an additional 376,196 shares during the period. Pura Vida Investments LLC boosted its holdings in Outset Medical by 8,482.4% in the second quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock valued at $8,243,000 after acquiring an additional 424,120 shares in the last quarter. Ensign Peak Advisors Inc boosted its holdings in Outset Medical by 272.4% in the second quarter. Ensign Peak Advisors Inc now owns 314,522 shares of the company’s stock valued at $6,042,000 after acquiring an additional 230,065 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in Outset Medical by 1,276.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 116,306 shares of the company’s stock valued at $1,642,000 after purchasing an additional 107,854 shares during the period.

Analysts Set New Price Targets

OM has been the subject of a number of recent research reports. Royal Bank Of Canada restated a “sector perform” rating and issued a $7.00 price objective on shares of Outset Medical in a report on Wednesday, December 17th. BTIG Research reiterated a “buy” rating and issued a $17.00 target price on shares of Outset Medical in a research report on Tuesday, December 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a research note on Monday, December 29th. Wall Street Zen cut Outset Medical from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Finally, Stifel Nicolaus decreased their price objective on Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.67.

Outset Medical Company Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.